NASDAQ:BOLT

Bolt Biotherapeutics Stock Forecast, Price & News

$11.78
-0.24 (-2.00 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.20
$11.95
50-Day Range
$11.78
$18.75
52-Week Range
$11.20
$43.07
Volume173,211 shs
Average Volume228,187 shs
Market Capitalization$428.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BOLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Bolt Biotherapeutics logo

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Headlines

Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Up 5%
Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Up 5%
July 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

456th out of 2,218 stocks

Pharmaceutical Preparations Industry

222nd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bolt Biotherapeutics (NASDAQ:BOLT) Frequently Asked Questions

Is Bolt Biotherapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bolt Biotherapeutics stock.
View analyst ratings for Bolt Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bolt Biotherapeutics?

Wall Street analysts have given Bolt Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bolt Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bolt Biotherapeutics' next earnings date?

Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Bolt Biotherapeutics
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Thursday, May, 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.22.
View Bolt Biotherapeutics' earnings history
.

What price target have analysts set for BOLT?

4 Wall Street analysts have issued 1 year price objectives for Bolt Biotherapeutics' stock. Their forecasts range from $33.00 to $45.00. On average, they anticipate Bolt Biotherapeutics' stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 239.6% from the stock's current price.
View analysts' price targets for Bolt Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bolt Biotherapeutics' key executives?

Bolt Biotherapeutics' management team includes the following people:
  • Dr. Randall C. Schatzman, CEO & Director (Age 66, Pay $706.05k)
  • Mr. William P. Quinn, Chief Financial Officer (Age 50, Pay $454.69k)
  • Dr. David Dornan Ph.D., Chief Scientific Officer (Age 43, Pay $422.5k)
  • Mr. Grant Yonehiro, Chief Bus. Officer (Age 57, Pay $434.07k)
  • Dr. Edith A. Perez M.D., Chief Medical Officer (Age 64, Pay $607.49k)
  • Dr. Edgar G. Engleman, Founder, Sec. & Director (Age 75)
  • Mr. Wesley Burwell, VP & Head of HR

Who are some of Bolt Biotherapeutics' key competitors?

What other stocks do shareholders of Bolt Biotherapeutics own?

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

When does the company's lock-up period expire?

Bolt Biotherapeutics' lock-up period expires on Wednesday, August 4th. Bolt Biotherapeutics had issued 11,500,000 shares in its IPO on February 5th. The total size of the offering was $230,000,000 based on an initial share price of $20.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $11.78.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics has a market capitalization of $428.06 million and generates $230,000.00 in revenue each year. The company earns $-60,730,000.00 in net income (profit) each year or ($22.26) on an earnings per share basis.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 65 workers across the globe.

What is Bolt Biotherapeutics' official website?

The official website for Bolt Biotherapeutics is www.boltbio.com.

Where are Bolt Biotherapeutics' headquarters?

Bolt Biotherapeutics is headquartered at 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-665-9295 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.